These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27074258)

  • 1. Correlation between TH1 response standard cytokines as biomarkers in patients with the delta virus in the western Brazilian Amazon.
    Nicolete LD; Borzacov LM; Vieira DS; Nicolete R; Salcedo JM
    Mem Inst Oswaldo Cruz; 2016 Apr; 111(4):275-6. PubMed ID: 27074258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
    Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H;
    Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
    Lutterkort GL; Wranke A; Hengst J; Yurdaydin C; Stift J; Bremer B; Hardtke S; Keskin O; Idilman R; Manns MP; Dienes HP; Falk C; Wedemeyer H; Heidrich B
    J Viral Hepat; 2018 Nov; 25(11):1384-1394. PubMed ID: 29888837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment.
    Mederacke I; Yurdaydin C; Dalekos GN; Bremer B; Erhardt A; Cakaloglu Y; Yalcin K; Gurel S; Zeuzem S; Zachou K; Bozkaya H; Dienes HP; Manns MP; Wedemeyer H;
    Antivir Ther; 2012; 17(2):305-12. PubMed ID: 22293066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir.
    Borzacov LM; de Figueiredo Nicolete LD; Souza LF; Dos Santos AO; Vieira DS; Salcedo JM
    Int J Infect Dis; 2016 May; 46():82-8. PubMed ID: 27005283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current management of delta hepatitis.
    Rizzetto M
    Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Th1/Th2 cytokines in serum on the pathogenesis of chronic hepatitis C and the outcome of interferon therapy.
    Zhang L; Hao CQ; Miao L; Dou XG
    Genet Mol Res; 2014 Nov; 13(4):9747-55. PubMed ID: 25501184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T helper type 1/T helper type 17-related cytokines in chronic hepatitis C patients before and after interferon and ribavirin therapy.
    Fathy A; Ahmed AS; Metwally L; Hassan A
    Med Princ Pract; 2011; 20(4):345-9. PubMed ID: 21576995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of and New Therapies for Hepatitis D.
    Koh C; Heller T; Glenn JS
    Gastroenterology; 2019 Jan; 156(2):461-476.e1. PubMed ID: 30342879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
    Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
    Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis D revival.
    Wedemeyer H
    Liver Int; 2011 Jan; 31 Suppl 1():140-4. PubMed ID: 21205152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
    Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
    Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis.
    Abdrakhman A; Ashimkhanova A; Almawi WY
    Antiviral Res; 2021 Jan; 185():104995. PubMed ID: 33321155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
    Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
    World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.
    Guedj J; Rotman Y; Cotler SJ; Koh C; Schmid P; Albrecht J; Haynes-Williams V; Liang TJ; Hoofnagle JH; Heller T; Dahari H
    Hepatology; 2014 Dec; 60(6):1902-10. PubMed ID: 25098971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response.
    Karaca C; Soyer OM; Baran B; Ormeci AC; Gokturk S; Aydin E; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S
    Antivir Ther; 2013; 18(4):561-6. PubMed ID: 22976528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
    Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
    World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.